LOS ANGELES, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Schall, Brown &amp; Schwartz LLP (&#34;SBS&#34;), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc.

ADMA

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

ADMA Faces Securities Class-Action Over Alleged Misstatements and Channel Stuffing

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>LOS ANGELES, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Schall, Brown &amp;amp; Schwartz LLP (&amp;#34;SBS&amp;#34;), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ADMA Biologics is named in a securities class-action alleging misstatements, undisclosed related-party transactions, and channel stuffing during 2024–2026. Lead-plaintiff filings are due by August 10, 2026. The suit could invite regulatory scrutiny and settlement costs, potentially weighing on sentiment, cash flow, and near-term ADMA stock volatility if the case progresses.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Schall, Brown &amp; Schwartz files class-action against ADMA; Aug 10, 2026 lead-plaintiff deadline.</li><li>Allegations: undisclosed related-party transaction; channel stuffing; weak internal controls.</li><li>Class Period: Aug 9, 2024 to Mar 25, 2026; case not certified yet.</li><li>Impact depends on case progress; potential settlements or regulatory scrutiny could affect sentiment and valuation.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ADMA Biologics, Inc. (ADMA)</strong>: Subject of securities class action; potential liability and stock volatility.</li><li><strong>Schall, Brown &amp; Schwartz LLP (N/A)</strong>: Plaintiff law firm; initiator of suit; no direct market exposure.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits due to securities litigation focus; potential near-term stock volatility tied to litigation milestones and settlement risk.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lead plaintiff deadline Aug 10, 2026 could trigger volatility for ADMA.</li><li>Case progress or settlement may move ADMA stock.</li><li>Case not certified yet; material impact depends on facts proven.</li><li>Broader biotech litigation sentiment could affect ADMA&#039;s risk premium.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Plaintiff firm: Schall, Brown &amp; Schwartz LLP.</li><li>Class Period: Aug 9, 2024 to Mar 25, 2026.</li><li>Deadline for lead-plaintiff filings: Aug 10, 2026.</li><li>Allegations: misstatements, undisclosed related-party transaction, channel stuffing.</li><li>Case not certified yet.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term downside risk on legal headlines; monitor for settlement or dismissal over coming months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="left">LOS ANGELES, Aug.  03, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=P3twgSd-sdKlruUWyOfQ6C-1BR129oz1EZaJ5diCtjQNF-tLW6jaAUs9pYvmEqYIYbgUotilvNb4rYajAhBabcRdjJW_z1oWql2qPjzxIvM73HFQ8P4Bc8cxBqbYRIeU" rel="nofollow" target="_blank">Schall, Brown &amp; Schwartz LLP</a> ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ADMA">ADMA</a>) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>  <p align="left">Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.</p>  <p align="left"><strong>CLASS PERIOD:</strong> August 9, 2024 to March 25, 2026</p>  <p align="left"><strong>DEADLINE: </strong>August 10, 2026</p>  <p align="left">If you are a shareholder who suffered a loss, <a href="https://www.globenewswire.com/Tracker?data=4BDT7Ut2asiTsHEMU-HWalwTD3Nhjbnz9qvxHmWiflL2nxMDGKF-eGUbr33h_9Lm-gs5fj9fh09ty4xjC_a8U7_sVrOnM0q9yQq4JqDraYpvcFR06DLxZNAFH_hp1swOHteDjIG0cDuupuFXwJ7f3A==" rel="nofollow" target="_blank">click here to participate</a>.</p>  <p align="left"><strong>CASE DETAILS: </strong>According to the Complaint, the Company made false and misleading statements to the market. ADMA engaged in a related party transaction it failed to disclose. The Company utilized channel stuffing to create the appearance of revenue. The Company failed to maintain appropriate internal controls. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about ADMA, investors suffered damages.</p>  <p align="left">We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown &amp; Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=GNody1xv-QSvnC-IpA-8MM6nmdU8qsCT9R2VP6rmp9z4WFa9pjINpAaBrbdGc99wNCvys4i2sjK1UZrgHQR5AuCSkbhrne0OTPrGNf1wwvU=" rel="nofollow" target="_blank"><u>www.schallfirm.com</u></a>, or by email at <a href="https://www.globenewswire.com/Tracker?data=QsqjuHPEG-NirBLbkXvUDE8CwJgfVUZwNoVDpHA7Z64XFvzQYkWPX8sGEFOec4dRL9XCRyJYSESFIurYTsqAdB4njMQQxeW0dRMpkrFE3Pw=" rel="nofollow" target="_blank">david@schallfirm.com</a>.</p>  <p align="left">The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>  <p align="left"><a href="https://www.globenewswire.com/Tracker?data=TtIhptrDLHtk6EOAXE-iY9rLwadyF4HtfobAjgQGmQevVORJNC-q0JAdiTM2H1LHWaUn1h8rAU7kOI7hGA_y8rySAF6FwljB7jcJqie4cVGU0fS63MxkbB1KwbVumedy" rel="nofollow" target="_blank">Join the case</a> to recover your losses</p>  <p align="left"><strong>WHY SBS?</strong> Schall, Brown &amp; Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.</p>  <p align="left">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        </p>  <p align="left"><strong>CONTACT:</strong></p>  <p align="left">Schall, Brown &amp; Schwartz LLP<br></br>Brian Schall, Esq.,<br></br>Andrew Brown, Esq.,<br></br>David Schwartz, Esq.,<br></br><a href="https://www.globenewswire.com/Tracker?data=GNody1xv-QSvnC-IpA-8MLEZl1WPjng6N635Jok3jTgNl-sHC67AQXY86qj9enLXvnGLYmzrL47BoCHIJnpgx6zbUZCrqc0tjW1ZOv3IjnQ=" rel="nofollow" target="_blank">www.schallfirm.com</a><br></br>Office: 310-301-3335<br></br><a href="https://www.globenewswire.com/Tracker?data=MY9pxuMJyYR2AZNGGnh7p5hLH_C89pI3t_2TfjSl1ytoFHgOCn7lu9x_mQ9gUqsGIMnVax6lkuzemYXIYyFwgSK1-cGBw_CCnRoGF_2mqNc=" rel="nofollow" target="_blank"><u>info@schallfirm.com</u></a></p>  <p align="left"><strong>SOURCE:</strong></p>  <p align="left"><strong> </strong>Schall, Brown &amp; Schwartz LLP</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwMjUwMiM3NzU1NjcyIzIxMjM4NjI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NjNhZDYzOWItOTAxNy00MjU2LWFiM2MtMWNjMTE4ODg1YWQ4LTExMzU0MzMtMjAyNi0wOC0wMy1lbg==/tiny/Schall-Law.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a"><img src="https://ml.globenewswire.com/media/0b1ae5f6-3843-4b48-9c73-0b3760ba856a/small/logo-sbs-jpg.jpg" border="0" width="150" height="145" alt="Primary Logo"></img></a></p>

ADMA Biologics is named in a securities class-action alleging misstatements, undisclosed related-party transactions, and channel stuffing during 2024–2026. Lead-plaintiff filings are due by August 10, 2026. The suit could invite regulatory scrutiny and settlement costs, potentially weighing on sentiment, cash flow, and near-term ADMA stock volatility if the case progresses.

News insight

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

AI summary

Sentiment rationale

Key facts

Legal